What are the ASCO guidelines for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)?

Updated: Nov 04, 2020
  • Author: Alexandre Chan, PharmD, MPH, FCCP, BCPS (AQ-ID), BCOP; more...
  • Print


Due to lack of high-quality, consistent evidence, the ASCO guidelines do not recommend any agents for prevention of CIPN. The guidelines strongly recommend that clinicians should not offer, and should discourage use of, acetyl-l-carnitine for the prevention of CIPN in patients with cancer. The guidelines also include a moderate recommendation against offering the following agents for the prevention of CIPN [2] :

  • All-trans retinoic acid
  • Amifostine
  • Amitriptyline
  • Calcium magnesium
  • Calmangafodipir
  • Cannabinoids
  • Carbamazepine
  • l-carnosine
  • Diethyldithiocarbamate (DDTC)
  • Gabapentin/pregabalin
  • Glutamate
  • Glutathione (GSH) for patients receiving paclitaxel/carboplatin chemotherapy
  • Goshajinkigan (GJG)
  • Metformin
  • Minocycline
  • N-acetylcysteine
  • Nimodipine
  • Omega-3 fatty acids
  • Org 2766
  • Oxcarbazepine
  • Recombinant human leukemia inhibitory factor
  • Venlafaxine
  • Vitamin B
  • Vitamin E

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!